Refine by
Lung Tumor Articles & Analysis
25 news found
"The emerging data being presented at ESMO are encouraging, as treatment with rigosertib plus nivolumab led to both complete and partial responses in patients with KRAS-mutated lung cancers who failed prior ICI therapy,” said Dr Rajwanth Veluswamy, the principal investigator of the study. ...
This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge diagnostic PARIS Test to first responders and other patients at Vincere Cancer Center. A patient’s tumor biopsy or surgical resection will be generated at Vincere and then sent to SEngine’s laboratory in Seattle, where up to 44 drugs from a library of over 240 options ...
SEngine's CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. ...
JBI-802 is a first-in-class, orally administered, dual equipotent inhibitor of LSD1 & HDAC6 JBI-802 demonstrated synergistic anti-tumor activity in animal models Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the dosing of the ...
There are more than 700,000 new lung cancer diagnoses annually in the U.S. and Europe. In approximately 25% of all lung cancer cases, the cancerous tumor resides only in a bronchus and not in the lobes of the lungs and is known as central lung cancer. ...
PD-1/PD-L1 activates human T cells to play an anti-tumor effect by releasing the inhibitory effect of tumor on cellular immunity. Its effectiveness is mainly reflected in malignant solid tumors, and it has been proved effective in a variety of malignant solid tumors. ...
This basket trial will include detection of circulating tumor DNA (ctDNA) across various solid tumors, including lung cancer, breast cancer, sarcoma and gastrointestinal (GI) cancers. ...
The American Lung Association recently released its 2021 State of Lung Cancer report. ...
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded ...
Live tumor models from a biopsy or surgical resection of a patient’s primary or metastatic brain tumor will be generated at the Dana-Farber Center for Patient Derived Models (CPDM) using methods they have established for maximizing the viability of brain tumor cells. ...
The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT (amivantamab-vmjw)*, ...
A plug&play interface between the two technologies will allow physiologically relevant exposure to complex aerosols in the background of an in vivo-like organization and breathing performance of the human lungs. The novel integrated HUMIMIC–InHALES test platform will allow acute and subchronic tests on lung models in combination with miniaturized human ...
“These data are very exciting because our HLA-independent TCR targeting mesothelin induced complete regression in a mouse tumor xenograft model and also outperformed a TRuC construct that we developed in-house,” said Karen Miller, SVP, Pipeline Research. ...
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session ...
The study, “T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts”, assessed anti-tumor synergy between PsiOxus’ T-SIGn® vectors and an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR)-T cell therapy from bluebird bio in xenograft ...
In the case study presented at AACR 2021, the patient’s tumor responded to Ibrutinib, a well-tolerated drug that could potentially help 10% of patients with ovarian ...
Sherman Oaks, CA – March 17, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based ...
The program is intended to launch in three categories: Population health screening and predictive analytics for conditions such as coronary arterial disease, stroke prevention and osteoporosis; Post-acute triage for urgent conditions such as pneumothorax, acute fractures and pneumonia (including COVID-19); and Routine peer review and quality assurance cases for conditions such as ...
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast ...